CCGs facing 'significant financial risk' after generic drug price surge

By Sharon Brennan2017-12-05T06:00:00

Clinical commissioning groups are facing “significant financial risk” this financial year due to supply issues pushing up the prices they have to pay for generic drugs.

You need to be a subscriber to read more

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

All HSJ news by sector, topic & region
Breaking News announcements
App for mobile and offline reading
Comment and Daily Insights newsletters
Regional roundup newsletters
10 expert briefings every fortnight (Premium only)
Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)

to HSJ

Already a subscriber? Sign into your account here